—These findings suggest that conventional imaging significantly underestimates the extent of disease in high-risk, biochemically recurrent prostate cancer, potentially impacting treatment decisions ...

The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation ...

Weill Cornell Medicine received a $1.5 million grant from the U.S. Department of Defense Prostate Cancer Research Program to develop new approaches for predicting the spread of cancer cells to the ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.